Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Study sponsor: Arrowhead Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-12Actual
Enrollment · participants4Actual
Source updated2025-11-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.